{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125385","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.741782+00:00","generated_at":"2026-05-30T01:51:23.126159+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints","bullets":["Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.","ODYSSEY Phase 2b of suprachoroidal CLS-AX in wet AMD met all primary and secondary outcomes with extended duration.","Cash, equivalents and short-term investments $23.6M as of Sep 30, 2024; runway into Q3 2025.","Asia-Pacific partner Arctic Vision licensed ARVN001 to Santen for China; Phase 3 UME data positive.","Tony Gibney appointed Chair of Board; REGENXBIO advances ABBV-RGX-314 via SCS Microinjector toward pivotal trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125385","json":"https://secwatch.observer/filing/0000950170-24-125385.json","markdown":"https://secwatch.observer/filing/0000950170-24-125385.md","text":"https://secwatch.observer/filing/0000950170-24-125385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/0000950170-24-125385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/clsd-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:51:23.126159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}